CAR-T treatment as the new hope for future cancer treatments
The core of CAR-T immunotherapy are the modification of immune cells to recognize and destroy cancer cells. One thing to look out for is this treatment often triggers cytokine release syndrome. Scientists are now promising new ways to use non-immune cells to mimic the ability of T cells in order to recognize and attack cancer cells.
The asking price of the Novartis cancer treatment is 14 million [2017-09-01╱ compiled Tang Shujun ╱ comprehensive foreign electricity] Swiss pharmaceutical group Novartis has created a way to strengthen the patient's autoimmune cells, changing the face of cancer therapy. They obtained FDA approval on August 30th. But the full course of treatment is $4,750,000 (about NT$14,350,000 million). The treatment, called "CLT019", was renamed "Kymriah" after approval. It belongs to a new type of therapy called "CAR-T", which takes disease-resistant T cells from the blood of patients and modifies their genes to make these cells better at recognizing and attacking cancer cells, and injecting them back into the patient for them to take effect. This treatment is said to significantly increase the survival rate of children and young patients with acute lymphoblastic leukemia (ALL).
